Platinum
Platinum is a chemical element whose coordination complexes have an established role in anticancer therapy.
Platinum is a chemical element whose coordination complexes have an established role in anticancer therapy. In oncology, “platinum” commonly refers to platinum-based chemotherapy, including cisplatin, carboplatin, and oxaliplatin. These agents form platinum–DNA adducts that disrupt DNA replication and transcription, producing DNA damage and, in susceptible cancer cells, apoptotic cell death. Platinum therapy is used across several malignancies, including ovarian cancer, lung cancer, breast cancer, and stomach cancer, and may be administered with other chemotherapy, radiation therapy, or immunotherapy.
The therapeutic value of platinum compounds is limited by toxicity, acquired or intrinsic resistance, and incomplete selectivity for cancer cells. Current research is therefore extending platinum therapy through redesigned Pt(II) complexes, drug-delivery systems, catalytic nanoparticles, and combination treatments intended to enhance cytotoxicity or overcome resistance. The supplied literature is concentrated on platinum therapy resistance, targeted cancer treatment strategies, and nanomedicine for cancer therapy, with particular attention to DNA-damage responses, RNA metabolism, tumor microenvironmental effects, and treatment selection in genetically defined cancers.
Where the papers sit
14 papers from the last 6 months study platinum directly · updated from PubMed 16 Nov 2026
Study type 2 clinical trials · 1 observational · 3 human data · 8 preclinical
Themes one subject
Those 14 are all about one subject.
-
Platinum Cancer Therapeutics
Platinum treatment research spans clinical chemotherapy, metallodrug design, targeted delivery and mechanisms of resistance. Newer approaches emphasize Pt(IV) prodrugs, Ferrocene conjugates, mesoporous carriers, ZIF-8 structures and nanozymes to improve tumor selectivity and limit toxicity. CDK12/13 inhibition may overcome platinum resistance by disrupting RNA metabolism, while BRCA status, EGFR mutations and treatment adherence shape clinical outcomes. The field remains focused on making platinum therapy more precise, durable and tolerable.
Papers
The 14 papers from the last 6 months that study platinum directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Platinum Cancer Therapeutics (14)
- Double-base deletions and signatures associated with platinum adducts in metastatic cancer. Nucleic acids research · 13 Oct 2026 PMID 42866949
- Rational design of anticancer metallodrugs. Journal of computer-aided molecular design · 26 Sept 2026 PMID 42799921
- Mesoporous silica nanocarrier-mediated delivery of Pt(II)-Ferrocene conjugates for enhanced antitumor activity and toxicity Mitigation. International journal of pharmaceutics · 24 Sept 2026 PMID 42785529
- Impact of center-level protocol adherence on neoadjuvant treatment outcome in pancreatic ductal adenocarcinoma. European journal of cancer (Oxford, England : 1990) · 15 Sept 2026 PMID 42743889
- Platinum chemotherapy ages the liver. Science (New York, N.Y.) · 10 Sept 2026 PMID 42721257
- Chemical Stabilization and Transformation of Schiff Base Scaffold: A Path toward Superior Platinum-Based Anti-Cancer Stem Cell Drugs. Journal of medicinal chemistry · 10 Sept 2026 PMID 42720472
- An Inhalable Hybrid Nitric Oxide Nanogenerator for Lung Adenocarcinoma Treatment via Bioorthogonal-Activated Gas-Immunotherapy. Journal of the American Chemical Society · 9 Sept 2026 PMID 42714559
- Green synthesis of CuO nanoparticles using mangrove leaves for targeted delivery of platinum (II) therapeutics. Scientific reports · 9 Sept 2026 PMID 42711436
- Design and optimization of Pt@ZIF-8 nanostructures via QbD approach: structural characterization and cytotoxic insights. Biomedical materials (Bristol, England) · 7 Sept 2026 PMID 42705336
- CDK12/13 inhibition overcomes platinum resistance by impairing RNA metabolism. Signal transduction and targeted therapy · 2 Sept 2026 PMID 42686681
- Chemotherapy type and survival in young BRCA1/2 carriers with HER2-negative early breast cancer. European journal of cancer (Oxford, England : 1990) · 11 Aug 2026 PMID 42580099
- Durvalumab plus etoposide-platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARD. Lung cancer (Amsterdam, Netherlands) · 26 Jun 2026 PMID 42361644
- A Platinum(IV) Metallo-Stapling Approach to Tumor-Specific Prodrugs for Targeted Chemo-Immunometabolic Cancer Therapy. Angewandte Chemie (International ed. in English) · 23 Jun 2026 PMID 42333893
- Atomic-Scale Full-Size Engineering of Platinum Nanozymes Enables High-Efficiency Catalytic Therapy. ACS nano · 22 Jun 2026 PMID 42328814
By study type
Clinical trials (2)
- Impact of center-level protocol adherence on neoadjuvant treatment outcome in pancreatic ductal adenocarcinoma. European journal of cancer (Oxford, England : 1990) · 15 Sept 2026 PMID 42743889
- Durvalumab plus etoposide-platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARD. Lung cancer (Amsterdam, Netherlands) · 26 Jun 2026 PMID 42361644
Observational studies and case reports (1)
- Chemotherapy type and survival in young BRCA1/2 carriers with HER2-negative early breast cancer. European journal of cancer (Oxford, England : 1990) · 11 Aug 2026 PMID 42580099
Human data, design not indexed (3)
- Double-base deletions and signatures associated with platinum adducts in metastatic cancer. Nucleic acids research · 13 Oct 2026 PMID 42866949
- Rational design of anticancer metallodrugs. Journal of computer-aided molecular design · 26 Sept 2026 PMID 42799921
- Atomic-Scale Full-Size Engineering of Platinum Nanozymes Enables High-Efficiency Catalytic Therapy. ACS nano · 22 Jun 2026 PMID 42328814
Preclinical: animal, cell and lab studies (8)
- Mesoporous silica nanocarrier-mediated delivery of Pt(II)-Ferrocene conjugates for enhanced antitumor activity and toxicity Mitigation. International journal of pharmaceutics · 24 Sept 2026 PMID 42785529
- Platinum chemotherapy ages the liver. Science (New York, N.Y.) · 10 Sept 2026 PMID 42721257
- Chemical Stabilization and Transformation of Schiff Base Scaffold: A Path toward Superior Platinum-Based Anti-Cancer Stem Cell Drugs. Journal of medicinal chemistry · 10 Sept 2026 PMID 42720472
- An Inhalable Hybrid Nitric Oxide Nanogenerator for Lung Adenocarcinoma Treatment via Bioorthogonal-Activated Gas-Immunotherapy. Journal of the American Chemical Society · 9 Sept 2026 PMID 42714559
- Green synthesis of CuO nanoparticles using mangrove leaves for targeted delivery of platinum (II) therapeutics. Scientific reports · 9 Sept 2026 PMID 42711436
- Design and optimization of Pt@ZIF-8 nanostructures via QbD approach: structural characterization and cytotoxic insights. Biomedical materials (Bristol, England) · 7 Sept 2026 PMID 42705336
- CDK12/13 inhibition overcomes platinum resistance by impairing RNA metabolism. Signal transduction and targeted therapy · 2 Sept 2026 PMID 42686681
- A Platinum(IV) Metallo-Stapling Approach to Tumor-Specific Prodrugs for Targeted Chemo-Immunometabolic Cancer Therapy. Angewandte Chemie (International ed. in English) · 23 Jun 2026 PMID 42333893
Written from 14 PubMed abstracts, each one listed by PMID above. Published: 2026-09-11. Last written: 2026-09-12 by GPT. Drafted by language models from published abstracts; not medical advice.